Literature DB >> 6755167

Insulin action and cirrhosis: insulin binding and lipogenesis in isolated adipocytes.

M S Harewood, J Proietto, F Dudley, F P Alford.   

Abstract

Insulin receptors and insulin stimulation of lipogenesis were studied in adipocytes from normal and cirrhotic subjects undergoing abdominal surgery. Despite the presence of hyperinsulinemia in the cirrhotic subjects, binding to receptors was not diminished compared to controls, whether expressed per cell number or cell size. Lipogenesis per cell surface area was higher basally (17.4 +/- 5.1 versus 3.8 +/- 1.6, p less than 0.05) and during maximal insulin stimulation (31.8 +/- 6.5 versus 10.4 +/0 3.9, p less than 0.01) in the cirrhotic subjects. However, cirrhotic and control adipocytes showed a similar increase above basal rates of lipogenesis with maximal insulin stimulation. The rate of lipogenesis was not correlated with fasting insulin level but was negatively correlated, basally (r = -0.61, p less than 0.05) and during maximal insulin stimulation (r = -0.52, p less than 0.05) with cell surface area. In contrast, insulin insensitivity, as quantified by ED50 for stimulation of lipogenesis, was positively correlated with fasting insulin level (r = 0.77, p less than 0.05) but was not related to cell size. It is concluded that the in vivo insulin resistance seen in cirrhosis is not due to any diminution in insulin binding or lipogenesis in adipocytes.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6755167     DOI: 10.1016/0026-0495(82)90011-7

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  9 in total

1.  Defective glucose utilization in patients with functioning beta-cell tumors persists after tumor excision.

Authors:  G S McGee; M M Kulaylat; N N Abumrad
Journal:  Ann Surg       Date:  1987-10       Impact factor: 12.969

2.  Insulin sensitivity in experimental cirrhosis.

Authors:  S A Chowdhury; R Taylor
Journal:  Mol Cell Biochem       Date:  1989-08-15       Impact factor: 3.396

3.  Insulin binding to erythrocytes in hyperinsulinemic patients with precirrhotic hemochromatosis and cirrhosis.

Authors:  A S Petrides; W Passlack; H Reinauer; W Stremmel; G Strohmeyer
Journal:  Klin Wochenschr       Date:  1987-09-15

4.  Hepatic kinome atlas: An in-depth identification of kinase pathways in liver fibrosis of humans and rodents.

Authors:  Justin F Creeden; Zachary A Kipp; Mei Xu; Robert M Flight; Hunter N B Moseley; Genesee J Martinez; Wang-Hsin Lee; Khaled Alganem; Ali S Imami; Megan R McMullen; Sanjoy Roychowdhury; Atta M Nawabi; Jennifer A Hipp; Samir Softic; Steven A Weinman; Robert McCullumsmith; Laura E Nagy; Terry D Hinds
Journal:  Hepatology       Date:  2022-04-08       Impact factor: 17.298

Review 5.  Pathogenesis of impaired glucose tolerance and type II diabetes mellitus--current status.

Authors:  M B Davidson
Journal:  West J Med       Date:  1985-02

6.  In vivo insulin action in hepatocellular and cholestatic liver cirrhosis.

Authors:  N Barzilai; P Cohen; E Karnieli; R Enat; O Epstein; J Owen; N McIntyre
Journal:  J Endocrinol Invest       Date:  1991-10       Impact factor: 4.256

7.  Nature and quantity of fuels consumed in patients with alcoholic cirrhosis.

Authors:  O E Owen; V E Trapp; G A Reichard; M A Mozzoli; J Moctezuma; P Paul; C L Skutches; G Boden
Journal:  J Clin Invest       Date:  1983-11       Impact factor: 14.808

8.  Mechanism of insulin resistance in human liver cirrhosis. Evidence of a combined receptor and postreceptor defect.

Authors:  P Cavallo-Perin; M Cassader; C Bozzo; A Bruno; P Nuccio; A M Dall'Omo; M Marucci; G Pagano
Journal:  J Clin Invest       Date:  1985-05       Impact factor: 14.808

Review 9.  Molecular mechanisms of metabolic associated fatty liver disease (MAFLD): functional analysis of lipid metabolism pathways.

Authors:  Olufunto O Badmus; Sarah A Hillhouse; Christopher D Anderson; Terry D Hinds; David E Stec
Journal:  Clin Sci (Lond)       Date:  2022-09-30       Impact factor: 6.876

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.